Strados Labs receives FDA 510(k) clearance for its wireless lung sound measurement platform, RESP™

by | Dec 22, 2020 | Press Releases

Philadelphia, PA December 22, 2020 — Strados Labs, a health technology developer of remote respiratory devices and software, today announced it has received FDA Class II 510(k) clearance for its first product, RESP™, a system for measuring, recording and analyzing lung sounds remotely across healthcare settings.

The RESP™ system has been used in clinical trials to help researchers quantify changes in lung sounds over time to compare against treatments, patient-reported outcomes, and other vital signs. The RESP™ can capture, store, and make available for clinical analysis these key changes in a patient’s lung sounds remotely with a small body-worn sensor and a cloud-based, HIPAA compliant software system. Dr. Mitchell Glass, the Chief Medical Officer of Strados Labs, said, “This wearable technology will allow us to follow our patients in healthcare settings more effectively, by providing regular interval listening between clinician visits, by archiving the patient’s lung sounds for future comparisons and by reducing the variability in auscultatory documentation that presents a major problem both in patient care and in clinical trials.”

The company is currently working with research organizations and pharmaceutical companies to capture lung sound measurements as primary and exploratory endpoints to support their trials. Strados Labs sees the use of RESP™ in trials to learn more about patient-reporting outcomes (ePRO) to help sponsors better understand how treatments and therapies impact patient symptoms like coughing or wheezing objectively. This system for remote lung measurement aligns with the sponsor goals of minimizing patient burden, maintaining patient privacy, and decentralizing trial data collection to optimize recruitment and retention.

“We are excited to finally bring the RESP™ technology to clinicians, scientists and patients who need it most,” said Co-founder & CEO Nick Delmonico. “The FDA clearance is a major milestone for our early-stage company. Our team worked tirelessly and overcame obstacles, many that were out of our control due to COVID19, to achieve this goal during a particularly challenging year for small businesses. We are thrilled to be one step closer to our mission of making every breath count.”

The RESP™ technology can be integrated into various health data systems, including telehealth, eICUs, clinical trial management platforms, and telemetry across healthcare settings. This is the company’s first FDA clearance.

Please visit or to learn more.

About Strados Labs

Strados Labs is a health technology company that is focused on enhancing our understanding of pulmonary diseases and respiratory health to fight disease progression and provide better patient care.

If you would like more information about the RESP platform for clinical research or pilots, please contact Alexis Taylor at (410) 929-6552, or email

RESP remote monitoring

Strados Labs Granted CE Mark for its RESP™ Smart Sensor Platform

CE Mark expands the company’s reach to support customers on a global scale Philadelphia, PA,...

Medtech Company, Strados Labs, Awarded National Science Foundation SBIR Phase II Grant

Funding will help Strados advance the power of its smart sensors to provide early detection and...

Strados Labs Named a Winner of 2022 Best of Sensors Awards

Recognized in the Wearable Category for the first-of-its-kind smart sensor platform for...

Upcoming Webinar: Advances in Digital Technology for Lung Health

Please join us for this free webinar sponsored by the American Thoracic Society (ATS) and part of...

Strados Labs, Growing Medtech Company, Raises $4.5M in Pre-series A Funding Round

Funding to fuel next key milestones as company continues to target asthma, COPD and infectious...

Procter & Gamble Health Care Veteran, Steve Bishop, Joins Strados Labs Board of Directors

Strados Labs harnesses the power of smart sensors and machine learning to aid in early detection...

Strados Labs Awarded Competitive Small Business Innovation Grant from the National Science Foundation

Small Business Innovation Research Program Provides Seed Funding for R&D Philadelphia, PA,...

Strados Labs Partners with Harris County Public Health Innovation Lab to Introduce One Breath at a Time Project for Pediatric Asthma Patients

Houston, TX and Philadelphia, PA, August 22, 2019 – An innovative program at Harris County Public...

Strados Labs Forms Collaboration with Boehringer Ingelheim for its Idiopathic Pulmonary Fibrosis (IPF) Pilot Study

Starting in early 2023 the biopharmaceutical company will use the Strados RESP™ Biosensor to...
Upcoming ATS Webinar: Advances in Digital Technology for Lung Health
This is default text for notification bar